Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

Simple item page
dc.contributor.authorMukonzo, Jackson K.
dc.contributor.authorOkwera, Alphonse
dc.contributor.authorNakasujja, Neoline
dc.contributor.authorLuzze, Henry
dc.contributor.authorSebuwufu, Deogratious
dc.contributor.authorOgwal-Okeng, Jasper
dc.contributor.authorWaako, Paul
dc.contributor.authorGustafsson, Lars L.
dc.contributor.authorAklillu, Eleni
dc.date.accessioned2021-12-15T06:59:51Z
dc.date.available2021-12-15T06:59:51Z
dc.date.issued2013
dc.description.abstractHIV infection, anti-tuberculosis and efavirenz therapy are associated with neuropsychological effects. We evaluated the influence of rifampicin cotreatment, efavirenz pharmacokinetics and pharmacogenetics on neuropsychiatric disorders in Ugandan HIV patients with or without tuberculosis coinfection. Methods: 197 treatment naïve Ugandan HIV patients, of whom 138 were TB co-infected, enrolled prospectively and received efavirenz based HAART. TB-HIV confected patients received concomitant rifampicin based anti-TB therapy. Genotypes for CYP2B6 (*6, *11), CYP3A5 (*3, *6, *7), ABCB1 (c.3435C>T and c.4036 A/G rs3842), CYP2A6 (*9, *17) and NR1I3 rs3003596 T/C were determined. Efavirenz plasma concentrations were serially quantified at 3rd day, 1st, 2nd, 4th, 6th, 8th and 12th weeks during therapy. Efavirenz neuropsychiatric symptoms were evaluated in terms of sleep disorders, hallucinations and cognitive effects at baseline, at two and twelve weeks of efavirenz treatment using a modified Mini Mental State Examination (MMSE) score.en_US
dc.identifier.citationMukonzo et al.: Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infectious Diseases 2013 13:261. doi:10.1186/1471-2334-13-261en_US
dc.identifier.other10.1186/1471-2334-13-261
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/526
dc.language.isoenen_US
dc.publisherBMC Infectious Diseasesen_US
dc.subjectEfavirenzen_US
dc.subjectNeuropsychiatric toxicityen_US
dc.subjectRifampicinen_US
dc.subjectCYP2B6en_US
dc.subjectHIVen_US
dc.subjectTuberculosisen_US
dc.subjectCNSen_US
dc.subjectAntiretroviral therapyen_US
dc.subjectUgandansen_US
dc.titleInfluence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort studyen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Influence of efavirenz pharmacokinetics and.pdf
Size:
300.55 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences